Ascendis Pharma A/S (NASDAQ:ASND) Short Interest Update

Ascendis Pharma A/S (NASDAQ:ASND) was the target of a large growth in short interest in October. As of October 31st, there was short interest totalling 3,410,000 shares, a growth of 5.6% from the October 15th total of 3,230,000 shares. Based on an average daily trading volume, of 634,100 shares, the short-interest ratio is presently 5.4 days.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ASND. SG Americas Securities LLC bought a new position in Ascendis Pharma A/S during the first quarter valued at $288,000. ProShare Advisors LLC grew its stake in shares of Ascendis Pharma A/S by 9.9% during the 1st quarter. ProShare Advisors LLC now owns 4,025 shares of the biotechnology company’s stock worth $608,000 after acquiring an additional 361 shares during the period. Acadian Asset Management LLC increased its holdings in Ascendis Pharma A/S by 1,461.1% in the 1st quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company’s stock worth $37,849,000 after acquiring an additional 234,446 shares during the last quarter. Bessemer Group Inc. lifted its holdings in Ascendis Pharma A/S by 61.0% during the first quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock valued at $132,000 after purchasing an additional 332 shares during the last quarter. Finally, Nan Fung Group Holdings Ltd bought a new position in Ascendis Pharma A/S during the first quarter worth about $2,056,000.

Ascendis Pharma A/S Trading Down 3.6 %

Shares of Ascendis Pharma A/S stock opened at $122.00 on Tuesday. The business’s fifty day simple moving average is $132.40 and its 200 day simple moving average is $132.47. Ascendis Pharma A/S has a 12 month low of $90.13 and a 12 month high of $161.00. The firm has a market capitalization of $7.40 billion, a P/E ratio of -15.10 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The company had revenue of $38.75 million for the quarter, compared to the consensus estimate of $94.74 million. Analysts predict that Ascendis Pharma A/S will post -7.3 EPS for the current fiscal year.

Analysts Set New Price Targets

ASND has been the topic of several recent research reports. Citigroup increased their price target on Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th. Wells Fargo & Company lifted their price target on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an “overweight” rating in a research report on Tuesday, September 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $170.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday. Bank of America boosted their target price on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a “buy” rating in a research report on Monday, September 23rd. Finally, Evercore ISI raised their price target on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an “outperform” rating in a research report on Tuesday, September 17th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $191.77.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.